This week’s update highlights four clinically relevant studies that were not central topics in the prior Belite report. The findings involve early treatment response, medication persistence, reduced-frequency maintenance dosing, bone health, and cardiovascular outcomes. Several are observational or exploratory and should not be interpreted as definitive practice-changing evidence.
- Rapid Early Weight Loss Did Not Appear to Create a New Safety Signal
Evidence status: Peer-reviewed post hoc analysis
A new analysis of the SURMOUNT-5 trial examined patients who lost weight particularly “rapidly” while receiving tirzepatide or semaglutide. The investigators evaluated whether rapid early weight reduction predicted greater long-term efficacy or increased adverse effects. Rapid responders and non-rapid responders were defined as participants that obtained ≥ 15% and < 15% body weight reduction by Week 24, respectively, noting that 24 weeks is 6 months.
The analysis found that patients with faster early weight loss generally achieved greater total weight reduction. Importantly, the investigators did not identify evidence that rapid responders experienced a fundamentally different safety profile, although gastrointestinal adverse effects remained common with both medications. Because this was a post hoc analysis rather than a prospectively designed trial, it cannot prove that rapid weight loss is safe in every patient or establish an optimal rate of loss. (PubMed)
Primary source: The American Journal of Medicine. DOI: 10.1016/j.amjmed.2026.03.010
(ScienceDirect)
Belite commentary
A strong early response is not automatically a reason to reduce an effective dose. The clinically relevant questions are whether the patient is adequately hydrated and nourished, tolerating treatment, preserving muscle, and avoiding excessive weakness, orthostatic symptoms, vomiting, or other complications.
The study does not establish that “faster is always better.” Rate of loss should still be interpreted in the context of age, baseline muscle mass, medical comorbidities, caloric and protein intake, and resistance exercise.
- Real-World Medicaid Data Show That Access and Persistence Remain Major Barriers
Evidence status: Peer-reviewed observational study
Researchers studied Massachusetts Medicaid members who began semaglutide or tirzepatide for overweight or obesity. At six months, approximately 61% remained persistent with treatment and about 60% met the study’s adherence definition. Among a highly persistent and adherent subgroup with available weight data, 86.5% lost at least 5% of their body weight. “Member-specific factors associated with lower rates of persistence and adherence included male sex, age (<40 years), diabetes, and a lack of weight-related comorbidities”. (PubMed)
Primary source: Journal of Managed Care & Specialty Pharmacy. DOI: 10.18553/jmcp.2026.32.3.271
Belite commentary
Clinical-trial efficacy does not automatically translate into real-world effectiveness. Patients must be able to obtain the medication consistently, tolerate it, follow the dose-escalation schedule, and remain engaged in follow-up care.
This study reinforces that interrupted coverage, high out-of-pocket cost, adverse effects, shortages, and fragmented care can materially reduce treatment benefit. The strong results among adherent patients are encouraging, but they may not represent the entire treated population because complete weight data were available only for a subgroup.
For practices, medication persistence should be treated as a clinical outcome. It deserves routine monitoring alongside weight, waist circumference, blood pressure, laboratory measures, nutritional adequacy, and adverse effects.
- Less-Frequent GLP-1 Dosing Maintained Weight in a Small Case Series
Evidence status: Peer-reviewed exploratory case series
A small case series reported on patients who transitioned to reduced-frequency GLP-1 treatment, mostly every other week, after reaching a weight plateau or treatment goal. Participants maintained reduced-frequency dosing for an average of approximately 36 weeks, with preservation of weight, body composition, and several metabolic improvements reported during follow-up. (PubMed)
Primary source: Obesity. DOI: 10.1002/oby.70137
(https://pubmed.ncbi.nlm.nih.gov/41732031/)
Belite commentary
This is clinically interesting because patients frequently ask whether they can use semaglutide or tirzepatide less often after reaching a maintenance phase.
However, this report is not sufficient to establish reduced-frequency dosing as a standard regimen. A case series has no randomized comparison group, may include unusually adherent or responsive patients, and cannot reliably identify uncommon adverse outcomes or determine which patients are suitable candidates.
Reduced-frequency treatment is also generally outside the FDA-approved dosing schedules for weekly semaglutide and tirzepatide. Any individualized maintenance strategy should consider symptom recurrence, appetite control, weight trajectory, medication pharmacology, cost, and the possibility that irregular dosing may increase gastrointestinal effects when treatment is resumed.
Practical conclusion: promising hypothesis, not yet established practice, but which may be helpful for certain patients.
- New Study Raises Questions About Hip Bone Loss During Treatment
Evidence status: Peer-reviewed retrospective study
A single-center study compared 255 adults using semaglutide or tirzepatide with 255 matched controls who had serial bone-density scans. The treatment group was predominantly female, had a mean age of 64, and lost a median of approximately 5% of body weight over a median 17-month follow-up. (PubMed)
Both treated patients and controls experienced declines in total-hip and femoral-neck bone mineral density. Among patients without diabetes, the GLP-1–treated group had slightly greater annualized total-hip bone loss than controls: approximately 1.0% versus 0.6%. Greater weight loss was associated with greater bone loss. The difference was not observed in the same manner among patients with diabetes. (PubMed)
Primary source: Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/clinem/dgag052
(PubMed)
Belite commentary
This study does not show that semaglutide or tirzepatide directly causes osteoporosis or fractures. It was retrospective, involved an older population already undergoing bone-density testing, and cannot fully separate medication effects from the skeletal consequences of weight reduction itself. The gold standard here would be a prospective randomized trial of the GLP-1 medications with a placebo control.
Nevertheless, it supports a prudent clinical approach, particularly for postmenopausal women, older adults, patients with low baseline bone density, and those losing weight rapidly:
- assess fracture and osteoporosis risk;
- ensure adequate protein, calcium, and vitamin D intake;
- encourage resistance and weight-bearing exercise;
- avoid unnecessary loss of lean mass;
- obtain bone-density testing when otherwise clinically indicated.
Routine DXA scanning solely because a patient starts a GLP-1 medication is not established by this study.
- Cardiovascular Comparison Produces an Interesting—but Nonrandomized—Result
Evidence status: Peer-reviewed real-world observational study
The STEER analysis used a large U.S. claims database to compare cardiovascular outcomes among people with overweight or obesity and established atherosclerotic cardiovascular disease, but without diabetes, who received semaglutide or tirzepatide.
Semaglutide use was associated with an earlier and statistically greater reduction in claims-based major cardiovascular outcomes than tirzepatide. However, the study was observational rather than randomized, and the investigators and publication disclosures included industry involvement. Residual confounding, differences in prescribing patterns, treatment duration, patient selection, and incomplete clinical information may have influenced the findings. (PubMed)
Primary source: Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.70436
(https://pubmed.ncbi.nlm.nih.gov/41491349/)
Belite commentary
This finding should not be interpreted as proof that semaglutide is superior to tirzepatide for cardiovascular prevention.
Semaglutide has randomized cardiovascular-outcomes evidence and an FDA indication for reducing major cardiovascular events in certain adults with cardiovascular disease and overweight or obesity. Tirzepatide’s definitive cardiovascular-outcomes evidence in broader populations remains under investigation. Observational comparisons can generate useful hypotheses but cannot substitute for direct randomized trials.
For a patient with established cardiovascular disease, medication selection should consider approved indications, individual risk factors, weight-loss response, tolerability, diabetes status, insurance coverage, and the totality of cardiovascular evidence—not this study alone.
Belite Clinical Takeaway
The most practical message this week is that treatment quality involves more than selecting a medication:
- Early rapid response can be acceptable, but nutrition, hydration, muscle preservation, and tolerability must be monitored.
- Medication effectiveness depends heavily on access and persistence.
- Reduced-frequency maintenance dosing is of interest, but not yet validated in controlled studies. This may be appropriate for selected patients.
- Bone health deserves attention in older or high-risk patients during substantial weight loss.
- Observational cardiovascular comparisons should not be mistaken for randomized evidence.
This News Flash is educational and does not replace individualized medical evaluation or prescribing advice.
